Catalyst Pharmaceuticals’ stockholders approved the proposed merger with Angelini Pharma at a special virtual meeting on July 8. The vote clears an important shareholder step toward completing the deal, which is likely to be modestly supportive for CPRX as M&A momentum builds.
Catalyst Pharmaceuticals’ stockholders approved the proposed merger with Angelini Pharma at a special virtual meeting on July 8. The vote clears an important shareholder step toward completing the deal, which is likely to be modestly supportive for CPRX as M&A momentum builds.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
